Samuel C. Blackman Sells 10,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $16.02, for a total value of $160,200.00. Following the completion of the sale, the insider now owns 1,174,662 shares of the company’s stock, valued at $18,818,085.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Day One Biopharmaceuticals Trading Up 2.8 %

Shares of DAWN traded up $0.42 during midday trading on Monday, hitting $15.38. 663,485 shares of the company’s stock traded hands, compared to its average volume of 645,529. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -6.46 and a beta of -1.48. Day One Biopharmaceuticals, Inc. has a 1 year low of $9.67 and a 1 year high of $17.85. The firm’s fifty day moving average is $15.22 and its 200-day moving average is $13.75.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, equities research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. The Goldman Sachs Group cut their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Piper Sandler reissued an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Finally, JPMorgan Chase & Co. raised their price objective on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $39.83.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of DAWN. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after acquiring an additional 1,445 shares during the last quarter. Fisher Asset Management LLC lifted its position in Day One Biopharmaceuticals by 89.0% during the fourth quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock valued at $999,000 after purchasing an additional 32,238 shares during the period. Wellington Management Group LLP lifted its position in Day One Biopharmaceuticals by 77.7% during the fourth quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock valued at $3,051,000 after purchasing an additional 91,393 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after purchasing an additional 472,654 shares during the last quarter. Finally, Quintet Private Bank Europe S.A. grew its position in Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.